“ Dexmedetomidine inhibits inflammation and angiogenesis and alleviates esophageal cancer progression through ITGA6/PI3K/AKT pathway: Dexmedetomidine inhibits esophageal cancer progression”, Indian J Exp Biol, vol. 64, no. 01, pp. 15–32, Feb. 2026, doi: 10.56042/ijeb.v64i01.22881.